Deutsche Bank Reiterates Buy, $46 Target on Teva Pharmaceuticals

Deutsche Bank maintains its Buy rating and $46 target on Teva Pharmaceuticals Industry, Ltd. TEVA on new sources of potential strength in 2012 EPS. Deutsche Bank says, “Teva recently implemented a series of unusually robust price increases for several legacy Cephalon branded products. Specifically, there were 15% price increases for Fentora and Provigil as of Oct 20. While the benefit on Provigil will be short lived as it is now just 4 months from being genericized, Teva raised the price of Nuvigil by a whopping 25% - on top of an 8% increase last May. Taken together, these recent increases could likely bolster the outlook for Teva's North American pharmaceutical sales in Q4 and more importantly, in 2012.” TEVA closed at $39.80 per share on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorReiterationPre-Market OutlookAnalyst RatingsDeutsche Bank
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!